Telehealth discussions about end-of-life care for patients with high grade glioma
Early Telehealth Visits for Discussion of Advanced Directives for Patients Newly Diagnosed With High Grade Glioma: Impact on Patient Care and Satisfaction
This study is trying to see if telehealth visits can help patients with high grade glioma and their families have important conversations about end-of-life care planning.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 50 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | University of Rochester Academic / other |
| Drugs / interventions | chemotherapy |
| Locations | 1 site (Rochester, New York) |
| Trial ID | NCT04543201 on ClinicalTrials.gov |
What this trial studies
This study aims to facilitate early discussions about advance care planning for patients newly diagnosed with high grade glioma through telehealth visits. Patients will receive a pre-visit educational guide and participate in a structured visit with trained providers using a checklist to ensure comprehensive discussions. The intervention will include family members or caregivers to support the patient during these critical conversations. The study will assess patient and caregiver perspectives, knowledge, satisfaction, and anxiety levels following the visit.
Who should consider this trial
Good fit: Ideal candidates are English-speaking patients with a new diagnosis of WHO grade III or IV glioma within four months of consent.
Not a fit: Patients with severe cognitive dysfunction or aphasia that prevents them from discussing advanced care planning will not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could improve the quality of end-of-life care for patients with high grade glioma by ensuring their wishes are documented and respected.
How similar studies have performed: While telehealth interventions for advance care planning are emerging, this specific structured approach for high grade glioma patients is relatively novel and has not been extensively tested.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * New pathologic diagnosis of WHO grade III or IV glioma within four months of consent * English speaking Exclusion Criteria: * Severe cognitive dysfunction or aphasia precluding discussion of advanced care planning issues
Where this trial is running
Rochester, New York
- University of Rochester — Rochester, New York, United States (Recruiting)
Study contacts
- Principal investigator: Sara Hardy, MD — University of Rochester
- Study coordinator: Sara Hardy, MD
- Email: Sara_Hardy@URMC.rochester.edu
- Phone: 585-273-4096
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.